Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2017-059
    NCT ID
    • NCT03073967
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase III
    Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug
    • Phase III
    Principal Investigator
    • Pranatharthi
      Chandrasekar, M.D.

      Infectious Diseases View Profile

    Objective:

    Primary:
    The primary objective of the trial is to show the efficacy of oral pritelivir 100 mg once a day in immunocompromised adults with ACV-resistant mucocutaneous HSV infections for a treatment period of 28 days as a maximum in comparison to foscarnet given as intermittent intravenous infusions at a dose of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours for a minimum of one hour duration for a maximum treatment duration of 28 days.
    Secondary:
    Secondary objective is to investigate the safety of oral pritelivir 100 mg once a day in immunocompromised adults with ACV-resistant mucocutaneous HSV infections for a treatment period of 28 days as a maximum in comparison to foscarnet given as intermittent intravenous infusions at a dose of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours for a minimum of one hour duration for a maximum treatment duration of 28 days.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266